104 related articles for article (PubMed ID: 20828695)
1. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
Kappelle PJ; Ahnström J; Dikkeschei BD; de Vries R; Sluiter WJ; Wolffenbuttel BH; van Tol A; Nielsen LB; Dahlbäck B; Dullaart RP
Atherosclerosis; 2010 Nov; 213(1):247-50. PubMed ID: 20828695
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
3. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
de Vries R; Dikkeschei BD; Sluiter WJ; Dallinga-Thie GM; van Tol A; Dullaart RP
Clin Lab; 2012; 58(11-12):1231-9. PubMed ID: 23289194
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
[TBL] [Abstract][Full Text] [Related]
5. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Voorbij HA; Sluiter WJ; van Tol A
Eur J Clin Invest; 2009 Mar; 39(3):200-3. PubMed ID: 19260949
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
[TBL] [Abstract][Full Text] [Related]
7. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
8. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
Milionis H
Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
[TBL] [Abstract][Full Text] [Related]
9. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
[TBL] [Abstract][Full Text] [Related]
10. Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case-control study.
Zhang P; Gao J; Pu C; Feng G; Wang L; Huang L; Tao Q; Zhang Y
Lipids Health Dis; 2016 Sep; 15(1):158. PubMed ID: 27633510
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Jeck T; Riesen WF; Keller U
Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Gavish D; Leibovitz E; Shapira I; Rubinstein A
J Intern Med; 2000 May; 247(5):563-9. PubMed ID: 10809995
[TBL] [Abstract][Full Text] [Related]
13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
14. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Michelena HI; Osorio LA; Citkowitz E
Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
18. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.
Ooi EM; Watts GF; Chan DC; Nielsen LB; Plomgaard P; Dahlbäck B; Barrett PH
Atherosclerosis; 2010 May; 210(1):326-30. PubMed ID: 20031132
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
Wanner C; Krane V
Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
